www.fdanews.com/articles/197488-abbvie-enters-partnership-to-develop-covid-19-antibody-therapies
AbbVie Enters Partnership to Develop COVID-19 Antibody Therapies
June 8, 2020
AbbVie has entered a partnership with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapy for COVID-19.
The partnership will advance the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM. The drugmaker will support its partners through preclinical activities while preparing for later-stage preclinical and clinical development work.
The company will have the option to exclusively license the antibody for therapeutic clinical development and commercialization worldwide.